Safety and efficacy of a programmed cell death 1 inhibitor combined with oxaliplatin plus S-1 in patients with Borrmann large type III and IV gastric cancers

doi:10.4251/wjgo.v16.i4.1281

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (478)

All Articles published online

The chart showing PDF series, HTML series, Tables (1-6) series.

Item

Count

PDF

HTML

327

Tables (1-6)

Sum=441

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=17

Apr 15, 2024 (publication date) through May 3, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Trials Study

World J Gastrointest Oncol. Apr 15, 2024; 16(4): 1281-1295
Published online Apr 15, 2024. doi: 10.4251/wjgo.v16.i4.1281

Table 1 Demographic data before surgery

Baseline variable	P-SOX group (n = 28)	SOX group (n = 61)	χ²	P value
Gender			0.080	0.777
Male	21 (75%)	44 (72.58%)
Female	7 (25%)	17 (27.42%)
Age			0.107	0.743
< 60	10 (35.71%)	24 (38.71%)
≥ 60	18 (64.29%)	37 (61.29%)
BMI			1.684	0.431
< 18.5	4 (14.29%)	10 (16.39%)
18.5-23	19 (67.86%)	33 (54.10%)
≥ 23	5 (17.86%)	18 (29.51%)
Tumor location			2.101	0.350
Upper	6 (21.43%)	15 (24.59%)
Middle	12 (42.86%)	33 (54.10%)
Lower	10 (35.71%)	13 (21.31%)
cT stage			0.297	0.586
T1/T2	5 (8.06%)	14 (22.58%)
T3/T4	23 (37.10%)	47 (77.42%)
cN stage			1.099	0.295
N0	3 (10.71%)	12 (19.67%)
N1-N3	25 (89.29%)	49 (80.32%)
cM stage			0.670	0.413
0	23 (82.14%)	54 (88.91%)
1	5 (17.86%)	7 (11.29%)
cTNM stage			0.351	0.554
I and II	7 (11.29%)	19 (32.26%)
III and IV	21 (33.87%)	42 (67.74%)
Neoadjuvant cycle			0.053	0.817
≤ 3	20 (71.43%)	45 (72.58%)
> 3	8 (28.57%)	16 (27.42%)
Operation mode			0.149	0.700
Open surgery	25 (89.29%)	56 (91.94%)
Laparoscopy	3 (10.71%)	5 (8.06%)
Adverse chemotherapy reaction			0.610	0.435
Yes	6 (21.43%)	9 (14.52%)
No	22 (78.57%)	52 (85.24%)
Differentiation			1.140	0.286
Well and middle	5 (17.86%)	6 (9.84%)
Poor and under-differentiated	23 (82.14%)	55 (90.16%)
Borrmann type			0.279	0.597
Big III	15 (53.58%)	29 (47.54%)
IV	13 (46.43%)	32 (52.46%)
AFP¹ (ng/mL)			0.566	0.452
≤ 8.1	20 (71.43%)	43 (70.49%)
> 8.1	2 (7.14%)	8 (13.11%)
Unknown	6 (21.43%)	10 (16.39%)
CEA¹ (ng/mL)			0.123	0.726
≤ 5	16 (57.14%)	35 (57.38%)
> 5	6 (21.43%)	16 (26.23%)
Unknown	6 (21.43%)	10 (16.39%)
CA199¹ (U/mL)			0.123	0.726
≤ 37	16 (57.14%)	35 (57.38%)
> 37	6 (21.43%)	16 (26.23%)
Unknown	6 (21.43%)	10 (16.39%)
CA724¹ (U/mL)			0.432	0.511
≤ 6.9	12 (42.86%)	32 (52.46%)
> 6.9	10 (35.71%)	19 (31.15%)
Unknown	6 (21.43%)	10 (16.39%)
CA125¹ (U/mL)			4.477	0.034^a
≤ 35	13 (46.43%)	42 (68.85%)
> 35	9 (32.14%)	9 (14.75%)
Unknown	6 (21.43%)	10 (16.39%)
CA50¹ (U/mL)			0.003	0.956
≤ 25	18 (64.29%)	42 (68.85%)
> 25	4 (14.29%)	9 (14.75%)
Unknown	6 (21.43%)	10 (16.39%)
Leukemia¹			0.228	0.892
≤ 3.5	1 (3.57%)	3 (4.92%)
3.5-9.5	19 (67.86%)	43 (70.49%)
> 9.5	3 (10.71%)	5 (8.20%)
Unknown	5 (8.20%)	10 (16.39%)
HGB¹			0.473	0.492
≤ 130	18 (64.29%)	36 (59.02%)
130-175	5 (8.20%)	15 (24.59%)
> 175	0	0
Unknown	5 (8.20%)	10 (16.39%)
Platelets¹			0.806	0.668
≤ 125	2 (7.14%)	2 (3.28%)
125-350	16 (57.14%)	39 (63.93%)
> 350	5 (8.20%)	10 (16.39%)
Unknown	5 (8.20%)	10 (16.39%)
Neutrophils¹			0.667	0.716
≤ 1.8	1 (3.57%)	4 (6.56%)
1.8-6.3	18 (64.29%)	41 (67.21%)
> 6.3	4 (14.29%)	6 (9.84%)
Unknown	5 (8.20%)	10 (16.39%)
Lymphocytes¹			0.084	0.772
≤ 1.1	8 (28.57%)	16 (26.23%)
1.1-3.2	15 (53.57%)	35 (57.38%)
> 3.2	0	0
Unknown	5 (8.20%)	10 (16.39%)
AFP² (ng/mL)			0.078	0.781
≤ 8.1	20 (71.43%)	46 (75.41%)
> 8.1	4 (14.29%)	11 (18.03%)
Unknown	4 (14.29%)	4 (6.56%)
CEA² (ng/mL)			2.806	0.094
≤ 5	22 (78.57%)	43 (70.49%)
> 5	2 (7.14%)	14 (22.95%)
Unknown	4 (14.29%)	4 (6.56%)
CA199² (U/mL)			0.507	0.476
≤ 37	22 (78.57%)	49 (80.33%)
> 37	2 (7.14%)	8 (13.11%)
Unknown	4 (14.29%)	4 (6.56%)
CA724² (U/mL)			2.034	0.154
≤ 6.9	18 (64.29%)	32 (52.46%)
> 6.9	6 (21.43%)	23 (37.70%)
Unknown	4 (14.29%)	6 (9.84%)
CA125² (U/mL)			0.043	0.835
≤ 35	23 (82.14%)	54 (88.52%)
> 35	1 (3.57%)	3 (4.92%)
Unknown	4 (14.29%)	4 (6.56%)
CA50² (U/mL)			0.583	0.445
≤ 25	22 (78.57%)	47 (77.05%)
> 25	2 (7.14%)	8 (13.11%)
Unknown	4 (14.29%)	6 (9.84%)
Leukemia²			1.181	0.554
≤ 3.5	7 (25%)	12 (19.67%)
3.5-9.5	16 (57.14%)	43 (70.49%)
> 9.5	3 (10.71%)	4 (6.56%)
Unknown	2 (7.14%)	2 (3.28%)
HGB²			0.662	0.416
≤ 130	23 (82.14%)	48 (78.69%)
130-175	3 (10.71%)	11 (18.03%)
Unknown	2 (7.14%)	2 (3.28%)
Platelets²			0.614	0.433
≤ 125	7 (25%)	21 (34.43%)
> 125	19 (67.86%)	38 (62.30%)
Unknown	2 (7.14%)	2 (3.23%)
Neutrophils²			0.730	0.673
≤ 1.8	6 (21.43%)	13 (21.31%)
1.8-6.3	17 (60.71%)	42 (68.85%)
> 6.3	3 (10.71%)	4 (6.56%)
Unknown	2 (7.14%)	2 (3.23%)

¹Tumor markers at first diagnosis.

²Preoperative tumor markers.

^aStatistically significant (P < 0.05).

SOX: S-1 + oxaliplatin; P-SOX: Programmed cell death 1 + S-1 + oxaliplatin; BMI: Body mass index; AFP: Alpha-fetoprotein; CEA: Carcinoembryonic antigen; CA199: Carbohydrate antigen199; HGB: Hemoglobin; cTNM: Clinical tumor node metastasis.

Table 2 Differences in response among the two groups

Baseline variable	P-SOX group (n = 28)	SOX group (n = 61)	P value
TRG			0.038
TRG0	4 (14.29%)	3 (4.92%)
TRG1	8 (28.57%)	8 (13.11%)
TRG2	13 (46.43%)	30 (49.18%)
TRG3	3 (10.71%)	20 (32.79%)
Subgroup analysis			0.013^a
TRG0/TRG1	12 (42.86%)	11 (18.03%)
TRG2/TRG3	16 (57.14%)	50 (81.97%)
ypT stage			0.272
0	4 (14.29%)	2 (3.23%)
1	1 (3.57%)	3 (4.92%)
2	6 (21.43%)	8 (13.11%)
3	2 (7.14%)	5 (8.20%)
4	15 (53.57%)	43 (70.49%)
ypN stage			0.130
0	11 (39.29%)	12 (19.67%)
1	5 (8.20%)	7 (11.48%)
2	5 (8.20%)	15 (24.59%)
3	7 (25%)	27 (44.26%)
ypM stage			0.099
	26 (92.86%)	48 (78.69%)
	2 (7.14%)	13 (21.31%)
ypTNM stage			0.196
pCR	4 (14.29%)	3 (4.92%)
I	4 (14.29%)	3 (4.92%)
II	4 (14.29%)	12 (19.67%)
III	13 (46.43%)	29 (47.54%)
IV	3 (10.71%)	14 (22.95%)
ypT stage			0.055
T0	4 (14.29%)	2 (3.28%)
T1-T4	24 (85.71%)	59 (96.72%)
ypN stage			0.05^a
N0	11 (39.29%)	12 (19.67%)
N1-N3	17 (60.71%)	49 (80.33%)
ypTNM stage			0.130
pCR	4 (14.29%)	3 (4.92%)
I-IV	24 (85.71%)	58 (95.08%)

^aStatistically significant (P < 0.05).

SOX: S-1 + oxaliplatin; P-SOX: Programmed cell death 1 + S-1 + oxaliplatin; pCR: Pathological complete response; TRG: Tumor regression grade.

Table 3 Clinicopathological results after surgery

Baseline variable	P-SOX group (n = 28)	SOX group (n = 61)	χ²	P value
Surgical approach			0.149	0.700
Laparoscopy	25 (89.29%)	56 (91.80%)
Open	3 (10.71%)	5 (8.20%)
Extent of resection			0.041	0.840
R0	23 (82.14%)	49 (80.33%)
R1	5 (17.86%)	12 (19.67%)
Nerve invasion			0.634	0.426
No	14 (50%)	25 (40.98%)
Yes	14 (50%)	36 (59.01%)
Vessel invasion			0.214	0.644
No	12 (42.86%)	23 (37.70%)
Yes	16 (57.14%)	38 (62.30%)
Harvested lymph nodes				0.354
Median	27.85 ± 10.27	31.45 ± 12.48
Positive lymph nodes				0.254
Median	4.71 ± 5.52	7.04 ± 8.84

SOX: S-1 + oxaliplatin; P-SOX: Programmed cell death 1 + S-1 + oxaliplatin.

Table 4 Postoperative complications

Baseline variable	P-SOX group (n = 28)	SOX group (n = 61)	P value
Total	5 (17.86%)	4 (6.56%)	0.101
Clavien-Dindo grading
Grade I-II	4	3	0.127
Fever	2	1	0.182
Lung infection	2	1	0.182
Pancreatic leakage	0	1	> 0.99
Cardiac insufficiency	0	1	> 0.99
Grade III	1	1	> 0.99
Anastomotic leakage	1	1	0.568
Grade IV	0	0	NA
Grade V	0	0	NA
Postoperative bleeding	94.82 ± 70.91	136.97 ± 119.59	0.020^a
Postoperative hospital stay	11.42 ± 5.67	11.20 ± 4.57	0.964

^aStatistically significant (P < 0.05).

SOX: S-1 + oxaliplatin; P-SOX: Programmed cell death 1 + S-1 + oxaliplatin; NA: Not available.

Table 5 Neoadjuvant treatment adverse effects

Baseline variable	P-SOX group (n = 28)	SOX group (n = 61)	χ²	P value
WHO grading
0	7 (25%)	16 (26.23%)	0.015	0.902
I	8 (28.57%)	21 (34.43%)	0.299	0.584
II	9 (32.14%)	15 (24.59%)	0.566	0.456
III	4 (14.29%)	9 (14.75%)	0.003	0.954
IV	0	0
WBC decreased			0.023	0.881
Grade 0, 1	24 (85.71%)	53 (86.88%)
Grade 2, 3, 4	4 (14.29%)	8 (13.11%)
HGB decreased			0.026	0.873
Grade 0, 1	22 (78.57%)	47 (77.05%)
Grade 2, 3, 4	6 (21.43%)	14 (22.95%)
Platelet count decreased			2.324	0.127
Grade 0, 1	24 (85.71%)	58 (95.08%)
Grade 2, 3, 4	4 (14.29%)	3 (4.92%)
Neutrophil count decreased			0.140	0.708
Grade 0, 1	24 (85.71%)	54 (88.52%)
Grade 2, 3, 4	4 (14.29%)	7 (11.48%)
Other adverse effects			0.458	0.499
Grade 0, 1	25 (89.29%)	59 (96.72%)
Grade 2, 3, 4	3 (10.71%)	2 (3.28%)

SOX: S-1 + oxaliplatin; P-SOX: Programmed cell death 1 + S-1 + oxaliplatin; WBC: White blood count; HGB: Hemoglobin.

Table 6 Comparison of tumor indexes between programmed cell death 1 + S-1 + oxaliplatin group and S-1 + oxaliplatin group before and after chemotherapy

	P-SOX group (n = 28)			SOX group (n = 61)
	First diagnosed	Preoperative	P value	First diagnosed	Preoperative	P value
AFP (ng/mL)			0.019^a			0.002^a
≤ 8.1	20 (71.43%)	20 (71.43%)		43 (70.49%)	46 (75.41%)
> 8.1	2 (7.14%)	4 (14.29%)		8 (13.11%)	11 (18.03%)
Unknown	6 (21.43%)	4 (14.29%)		10 (16.39%)	4 (6.56%)
CEA (ng/mL)			0.211			0.405
≤ 5	16 (57.14%)	22 (57.14%)		35 (57.38%)	43 (70.49%)
> 5	6 (21.43%)	2 (21.43%)		16 (26.23%)	14 (22.95%)
Unknown	6 (21.43%)	4 (14.29%)		10 (16.39%)	4 (6.56%)
CA199 (U/mL)			0.232			0.181
≤ 37	16 (57.14%)	22 (57.14%)		36 (59.02%)	49 (80.33%)
> 37	6 (21.43%)	2 (21.43%)		15 (24.59%)	8 (13.11%)
Unknown	6 (21.43%)	4 (14.29%)		10 (16.39%)	4 (6.56%)
CA724 (U/mL)			0.356			0.552
≤ 6.9	12 (42.86%)	18 (42.86%)		32 (52.46%)	32 (52.46%)
> 6.9	10 (35.71%)	6 (35.71%)		19 (31.15%)	23 (37.70%)
Unknown	6 (21.43%)	4 (14.29%)		10 (16.39%)	6 (9.84%)
CA125 (U/mL)			0.005^a			0.023^a
≤ 35	13 (46.43%)	23 (82.14%)		42 (68.85%)	54 (88.52%)
> 35	9 (32.14%)	1 (3.57%)		9 (14.75%)	3 (4.92%)
Unknown	6 (21.43%)	4 (14.29%)		10 (16.39%)	4 (6.56%)
CA50 (U/mL)			0.301			0.915
≤ 25	18 (64.29%)	22 (64.29%)		42 (68.85%)	47 (77.05%)
> 25	4 (14.29%)	2 (14.29%)		9 (14.75%)	8 (13.11%)
Unknown	6 (21.43%)	4 (14.29%)		10 (16.39%)	6 (9.84%)
Leukemia			0.366			0.005^a
≤ 3.5	1 (3.57%)	7 (25%)		3 (4.92%)	12 (19.67%)
3.5-9.5	19 (67.86%)	16 (57.14%)		43 (70.49%)	43 (70.49%)
> 9.5	3 (10.71%)	3 (10.71%)		5 (8.20%)	4 (6.56%)
Unknown	5 (8.20%)	2 (7.14%)		10 (16.39%)	2 (3.28%)
HGB			0.094			0.045^a
≤ 130	18 (64.29%)	23 (82.14%)		36 (59.02%)	48 (78.69%)
130-175	5 (8.20%)	3 (10.71%)		15 (24.59%)	11 (18.03%)
> 175	0	0		0	0
Unknown	5 (8.20%)	2 (7.14%)		10 (16.39%)	2 (3.28%)
Platelets			0.001^a			0.001^a
≤ 125	2 (7.14%)	7 (25%)		2 (3.28%)	21 (34.43%)
125-350	16 (57.14%)	19 (67.86%)		39 (63.93%)	35 (57.38%)
> 350	5 (8.20%)	0		10 (16.39%)	3 (4.92%)
Unknown	5 (8.20%)	2 (7.14%)		10 (16.39%)	2 (3.28%)
Neutrophils			0.077			0.005^a
≤ 1.8	1 (3.57%)	6 (21.43%)		4 (6.56%)	13 (21.31%)
1.9-6.3	18 (64.29%)	17 (60.71%)		41 (67.21%)	42 (68.85%)
> 6.3	4 (14.29%)	3 (10.71%)		6 (9.84%)	4 (6.56%)
Unknown	5 (8.20%)	2 (7.14%)		10 (16.39%)	2 (3.28%)

^aStatistically significant (P < 0.05).

SOX: S-1 + oxaliplatin; P-SOX: Programmed cell death 1 + S-1 + oxaliplatin; AFP: Alpha-fetoprotein; CEA: Carcinoembryonic antigen; CA199: Carbohydrate antigen199; HGB: Hemoglobin.

Citation: Bao ZH, Hu C, Zhang YQ, Yu PC, Wang Y, Xu ZY, Fu HY, Cheng XD. Safety and efficacy of a programmed cell death 1 inhibitor combined with oxaliplatin plus S-1 in patients with Borrmann large type III and IV gastric cancers. World J Gastrointest Oncol 2024; 16(4): 1281-1295
URL: https://www.wjgnet.com/1948-5204/full/v16/i4/1281.htm
DOI: https://dx.doi.org/10.4251/wjgo.v16.i4.1281